Carcinoma, Non-Small-Cell Lung: all 6,645 studies

Page 40 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.

• Baduanjin Exercise on Meridian Energy, Lung Function and Heart Rate Variability in Patients Undergoing Lung Operative.Status unknownNCT04669730Not applicable
• The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard TherapyStatus unknownNCT04667975Phase 1
• Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United KingdomCompletedNCT04667312
• Expanded Access of SotorasibNo longer availableNCT04667234
• A Study of SGN-STNV in Advanced Solid TumorsTerminatedNCT04665921Phase 1
• CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsActive, not recruitingNCT04660929Phase 1
• A Randomized Study of Primary Tumor Radiotherapy for Patients With Stage Ⅳ NSCLCStatus unknownNCT04654520Not applicable
• Lung Cancer RegistryCompletedNCT04654364
• Total-body PET/CT Imaging Using the uEXPLORER in Non-small Cell Lung Cancer Patients Treated by Induction Chemotherapy Plus Nivolumab and Definitive Concurrent ChemoradiotherapyCompletedNCT04654234
• SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung CancerWithdrawnNCT04650490Phase 2
• A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT04647344Phase 1/2
• Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics ModelsStatus unknownNCT04646837Phase 1/2
• Almonertinib With Chemotherapy in mEGFR NSCLCStatus unknownNCT04646824Phase 2
• Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingNCT04644068Phase 1/2
• A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain MetastasesStatus unknownNCT04643847Phase 2
• A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung CancerStatus unknownNCT04641754Phase 2
• Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC.CompletedNCT04640935
• The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With AfatinibCompletedNCT04640870
• ARGONAUT: Stool and Blood Sample Bank for Cancer PatientsSuspendedNCT04638751
• Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04638582Phase 2
• A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLCStatus unknownNCT04636593Phase 2
• The Influence of Cancer Stem-cells on Risk of Relapse in Patients Harboring Adenocarcinoma and Squamous Cell Carcinoma of the LungCompletedNCT04634630
• Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingNCT04632758Phase 3
• Efficacy and Safety of Camrelizumab in Real-World StudyStatus unknownNCT04631146
• Supportive Care Mobile Application for Patients With NSCLCCompletedNCT04629300Not applicable
• Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLCStatus unknownNCT04629027
• Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant TreatmentWithdrawnNCT04625699Phase 2
• Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Active, not recruitingNCT04625647Phase 2
• XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT04622072Phase 1
• Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)Active, not recruitingNCT04622007Phase 2
• A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung CancerCompletedNCT04620330Phase 2
• A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer PatientsStatus unknownNCT04619563Phase 2
• A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung CancerStatus unknownNCT04619537Phase 2
• Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer PatientsWithdrawnNCT04615884Not applicable
• Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line ChemotherapyStatus unknownNCT04613804Phase 2
• Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04612751Phase 1
• A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLCStatus unknownNCT04612673Phase 2
• A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung CancerWithdrawnNCT04611776Phase 2
• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsCompletedNCT04609566Phase 2
• A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid TumorsActive, not recruitingNCT04606472Phase 1
• A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.Status unknownNCT04606303Phase 2
• A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesActive, not recruitingNCT04603807Phase 3
• A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial TumorsActive, not recruitingNCT04603287Phase 1
• Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung CancerApproved for marketingNCT04599712
• Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)Active, not recruitingNCT04597671Phase 3
• Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.Status unknownNCT04595734
• Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung CancerStatus unknownNCT04592666Phase 2
• A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South KoreaCompletedNCT04592523
• Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung CancerCompletedNCT04589013
• Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLCStatus unknownNCT04586465Phase 2
• Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)SuspendedNCT04585477Phase 2
• A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLCActive, not recruitingNCT04580498Phase 2
• INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsCompletedNCT04580485Phase 1
• Accelerated Radio-Immunotherapy for Lung CancerCompletedNCT04577638Phase 2
• A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788WithdrawnNCT04576208Phase 2
• Special Drug Use-results Surveillance of Tabrecta TabletsCompletedNCT04575025
• Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid TumorsStatus unknownNCT04571632Phase 2
• Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC PatientsCompletedNCT04566432
• New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapyActive, not recruitingNCT04564157Phase 3
• Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)CompletedNCT04563871Phase 2
• A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line TreatmentStatus unknownNCT04560244Phase 2
• Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II TrialStatus unknownNCT04553887Phase 2
• Molecular Imaging Visualization of Tumor Heterogeneity in Non-small Cell Lung CancerStatus unknownNCT04553601Not applicable
• Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC PatientsCompletedNCT04552613Not applicable
• Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLCTerminatedNCT04549428Phase 2
• Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing RegimenTerminatedNCT04549025Phase 2
• PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %Active, not recruitingNCT04547504Phase 3
• A Phase 1 Study of GNR-051 in Subjects With Advanced MalignanciesCompletedNCT04544748Phase 1
• A Study of Combination Therapy in NSCLCStatus unknownNCT04544644Phase 2
• Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLCStatus unknownNCT04541251Phase 2
• Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer SurgeryActive, not recruitingNCT04536675Phase 3
• An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion MutationsApproved for marketingNCT04535557
• Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLCStatus unknownNCT04530097Not applicable
• Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)CompletedNCT04529564
• ENCOrafenib With Binimetinib in bRAF NSCLCActive, not recruitingNCT04526782Phase 2
• Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)Active, not recruitingNCT04526691Phase 1
• Study of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLCStatus unknownNCT04524299Phase 2
• PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)TerminatedNCT04524195Phase 1
• Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) SubjectsTerminatedNCT04515979Phase 2
• Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKITerminatedNCT04510415Phase 1
• Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung CancerNo longer availableNCT04507919
• NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung CancerActive, not recruitingNCT04505267Phase 1
• First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursCompletedNCT04504669Phase 1
• A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ TumorsActive, not recruitingNCT04503278Phase 1
• Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)CompletedNCT04501497
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene MutationStatus unknownNCT04500717Phase 3
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLCStatus unknownNCT04500704Phase 3
• A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence TherapyCompletedNCT04500535
• CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCActive, not recruitingNCT04495153Phase 2
• Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/MelanomaCompletedNCT04490564
• Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of ChemotherapyCompletedNCT04487457
• Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung CancerStatus unknownNCT04487093Phase 1
• Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung CarcinomaWithdrawnNCT04485026Phase 2
• SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph IICompletedNCT04480372Phase 2
• Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung CancerCompletedNCT04479306Phase 1
• Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside SitesTerminatedNCT04474613Not applicable
• KN046 in Subjects With Advanced Squamous Non-small Cell Lung CancerStatus unknownNCT04474119Phase 3
• Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC PatientsStatus unknownNCT04473703
• Study to Investigate DRP-104 in Adults With Advanced Solid TumorsTerminatedNCT04471415Phase 1/2
• Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating MutationStatus unknownNCT04470076Phase 2

← Carcinoma, Non-Small-Cell Lung overview